Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BLTE | 6-K | bullish | 7/10 | Belite Bio reported Q2 2026 financial results alongside the key catalyst that the FDA accepted its NDA with Priority Rev | Aug 13, 2026 |
| AGEN | 8-K | neutral | 2/10 | Agenus granted Chairman/CEO Garo Armen a one-time performance-based stock option award of 1,971,500 options with a $7.78 | Aug 13, 2026 |
| IMRN | 6-K | neutral | 2/10 | Immuron Ltd filed a 6-K announcing that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on | Aug 13, 2026 |
| REGN | CLUSTER | neutral | 2/10 | Two Regeneron directors sold a combined $960K in open-market sales on August 10, 2026, following the exercise of stock o | Aug 13, 2026 |
| REPL | CLUSTER | mixed | 6/10 | Replimune insiders (CEO, CFO, CMO, CAO) sold $906K in open-market sales on August 10, 2026, the same day as a $150M dilu | Aug 13, 2026 |
| MEDP | CLUSTER | neutral | 3/10 | CEO August Troendle sold $14M in open-market sales over two days (Aug 10-11), and a director sold $465K after exercising | Aug 13, 2026 |
| LTGO | CLUSTER | bullish | 5/10 | Two insiders at Latigo Biotherapeutics (LTGO) made open-market purchases totaling $5.04M at $18.00/share on August 10, 2 | Aug 13, 2026 |
| CRBP | CLUSTER | neutral | 3/10 | A mixed insider cluster at Corbus Pharmaceuticals shows the CEO and CFO selling a combined $292K in open-market sales on | Aug 13, 2026 |
| MRK | CLUSTER | neutral | 2/10 | Multiple Merck executives, including the EVP of Animal Health, EVP of Access/Policy/Comms, EVP/Chief Digital Officer, an | Aug 13, 2026 |
| TAK | CLUSTER | neutral | 3/10 | A cluster of 13 Takeda insiders, including the CEO and President of R&D, sold a total of $8.64M in open-market sales on | Aug 13, 2026 |
| MIRM | CLUSTER | neutral | 3/10 | Mirum Pharmaceuticals CEO Christopher Peetz and CFO Eric Bjerkholt sold a combined $1.75M in open-market stock within tw | Aug 13, 2026 |
| ERAS | INST-CLUSTER | bullish | 6/10 | A strong institutional cluster formed in ERAS during 2026-Q2, with 16 buyers accumulating $104.2M net against just 1 sel | Aug 13, 2026 |
| EOLS | INST-CLUSTER | bullish | 5/10 | Five institutional investors accumulated $11.6M in net new EOLS positions during Q2 2026, led by State Street (+$6.4M) a | Aug 13, 2026 |
| ESPR | INST-CLUSTER | bearish | 5/10 | Esperion Therapeutics (ESPR) saw a mixed institutional cluster in 2026-Q2: 6 buyers (net +$5.0M) led by JPMorgan doublin | Aug 13, 2026 |
| CORT | CLUSTER | neutral | 4/10 | Three Corcept insiders, including Chief Development Officer William Guyer, sold a total of $3.81M in open-market sales o | Aug 13, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt executed a large option exercise and sold a significant block of shares (net ~$6.4M in open-market | Aug 13, 2026 |
| ICLR | CLUSTER | neutral | 2/10 | Seven ICON PLC insiders, including the CEO and CFO, sold a total of ~$237K in open-market sales over a one-week window. | Aug 13, 2026 |
| BLSM | CLUSTER | bullish | 8/10 | A cluster of insider open-market purchases totaling $5.14M occurred at BlossomHill Therapeutics on August 10, 2026. Dire | Aug 13, 2026 |
| ABT | COURT-RULING | neutral | 2/10 | The district court overruled the relator's objections and affirmed a magistrate judge's order requiring the relator to p | Aug 13, 2026 |
| OTLK | PRESS-RELEASE | bearish | 7/10 | Outlook Therapeutics priced a dilutive underwritten public offering of 55.6M shares and warrants at $0.99/unit, raising | Aug 12, 2026 |
| BLTE | PRESS-RELEASE | neutral | 6/10 | Belite Bio reported Q2 2026 results with a GAAP net loss of $28.4M ($0.70 per ADS), wider than the $0.78 consensus estim | Aug 12, 2026 |
| HEPA | CLUSTER | bullish | 6/10 | Two Hepion insiders, including the Interim CEO and a director, purchased a total of $125K in HEPA shares at $0.05 each o | Aug 12, 2026 |
| TAK | CLUSTER | neutral | 2/10 | A cluster of 4 Takeda insiders (including C-suite executives) sold shares on August 10, 2026, totaling $1.47M. The broad | Aug 12, 2026 |
| AMGN | CLUSTER | neutral | 2/10 | Two SVPs at Amgen sold a combined $1.63M in open-market sales on August 6, 2026. The total value represents ~0.0007% of | Aug 12, 2026 |
| MLYS | 3 | neutral | 2/10 | James J. Ferguson III filed an initial statement of beneficial ownership (Form 3) with the SEC, disclosing his appointme | Aug 12, 2026 |
| SEPN | 144 | bearish | 5/10 | RA Capital Healthcare Fund LP, a major pre-IPO investor in Septerna, filed a Form 144 on August 12, 2026, signaling inte | Aug 12, 2026 |
| RPRX | 144 | neutral | 3/10 | Errol B. De Souza, a former affiliate of Royalty Pharma, filed two Form 144 notices on August 12, 2026, signaling intent | Aug 12, 2026 |
| SEPN | 144 | bearish | 5/10 | RA Capital Nexus Fund III, L.P., a major pre-IPO institutional investor in Septerna, filed a Form 144 on August 12, 2026 | Aug 12, 2026 |
| ANRO | INST-CLUSTER | bullish | 6/10 | Seven institutional investors, led by BlackRock, State Street, and Geode, collectively added $67.0M in new ANRO holdings | Aug 12, 2026 |
| ANAB | INST-CLUSTER | bullish | 5/10 | Seven institutional investors accumulated $73.2M in net new ANAB positions during Q2 2026, led by State Street (+$31.8M) | Aug 12, 2026 |